

## 血液透析患者静脉导管感染病原菌的分布及感染因素分析

张贊<sup>1</sup>, 李娅<sup>1</sup>, 孟梅霞<sup>2</sup>, 张莉<sup>2</sup>

(西安交通大学附属广仁医院检验科<sup>1</sup>, 透析中心<sup>2</sup>, 陕西 西安 710004)

**【摘要】** 目的 探讨血液透析患者导管相关感染的感染因素, 病原菌的分布特点及其耐药情况, 为临床合理使用抗生素提供指导。方法 回顾性分析2013年6月至2015年6月期间在我院透析中心就诊的178例血液透析患者的临床资料、细菌培养情况, 分析感染的危险因素和病原菌分布特点。结果 178例血液透析患者中发生导管相关感染者29例, 感染率为16.29%, 感染患者以年龄>60岁和长期留置管为主; 共分离出77株病原菌, 其中革兰氏阳性球菌占61.04%, 革兰氏阴性杆菌占38.96%; 主要致病菌为凝固酶阴性的葡萄球菌, 金黄色葡萄球菌, 大肠埃希菌和肠球菌; 革兰氏阳性球菌对红霉素、克林霉素的耐药率较高, 均>50%; 革兰氏阴性杆菌对氨苄西林、头孢唑啉的耐药, 耐药率均>50%。结论 血液透析患者免疫力低下, 易发生感染, 临床应加强对导管相关感染的监测, 重视导管相关感染的早期诊断, 积极采取措施, 预防导管相关血行感染的发生。

**【关键词】** 血液透析; 感染因素; 导管相关感染; 细菌分布; 耐药性

**【中图分类号】** R459.5    **【文献标识码】** A    **【文章编号】** 1003—6350(2016)12—1978—03

**Analysis of infection factors and pathogenic bacteria of venous catheter related infections in hemodialysis patients.** ZHANG Yun<sup>1</sup>, LI Ya<sup>1</sup>, MENG Mei-xia<sup>2</sup>, ZHANG Li<sup>2</sup>. Department of Clinical Laboratory<sup>1</sup>, Dialysis Center<sup>2</sup>, Guangren Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi, CHINA

**[Abstract]** **Objective** To investigate the infection factors and distribution of pathogenic bacteria and drug resistance in patients with hemodialysis, and provide guidance for clinical rational use of antibiotics. **Methods** A total of 178 patients who underwent hemodialysis in our hospital from June 2013 to June 2015 were retrospectively evaluated,

基金项目: 陕西省卫生厅科技基金资助项目(编号: 2010H17)

通讯作者: 张贊。E-mail: 26076787@qq.com

\*\*\*\*\*

完全抑制住舒芬太尼诱发的呛咳反应, 且存在额外增加患者经济负担或产生其他并发症的缺点。本实验结果显示, 当采用丙泊酚靶控输注及舒芬太尼静注行全麻诱导时, 采用效应室浓度为2.0 μg/mL的丙泊酚靶控输注时, 并不能明显降低呛咳发生率, 当增加效应室浓度至3.0 μg/mL、4.0 μg/mL时, 可将舒芬太尼的呛咳发生率从26%分别下降至16%及6%。

综上所述, 采用效应室靶控浓度为3.0 μg/mL及4.0 μg/mL的丙泊酚靶控输注均能有效地抑制舒芬太尼诱发的呛咳反应, 但4.0 μg/mL组的呛咳发生率更低。

### 参 考 文 献

- [1] Agarwal A, Gautam S, Nath SS, et al. Comparison of the incidence and severity of cough induced by sufentanil and fentanyl: a prospective, randomised, double-blind study [J]. Anesthesia, 2007, 62(12): 1230-1232.
- [2] Tweed WA, Dakin D. Explosive coughing after bolus fentanyl injection [J]. Anesth Analg, 2001, 92(6): 1442-1443.
- [3] Sediqhinejad A, Naderi Nabi B, Haqiqihi M, et al. Propofol is effective to depress fentanyl-induced cough during induction of anesthesia [J]. Anaesth Pain Med, 2013, 2(4): 170-173.
- [4] Marsh B, White M, Morton N, et al. Pharmacokinetic model driven infusion of propofol in children [J]. British Journal of Anaesthesia, 1991, 67(1): 41-48.
- [5] Tsutomu O, Yoshiko K, Yasuhisa O, et al. Identification of independent risk factors for fentanyl-induced cough [J]. Can J Anaesth, 2006, 53(8): 753.
- [6] Agarwal A, Azim A, Ambesh S, et al. Salbutamol, beclomethasone or sodium chromoglycate suppress coughing induced by iv fentanyl [J]. Canadian Journal of Anesthesia, 2003, 50(3): 297-300.
- [7] Kim JY, Lee SY, Kim DH, et al. Effect-site concentration of propofol for reduction of remifentanil-induced cough [J]. Anaesthesia, 2010, 65(7): 697-703.
- [8] Liu XS, Xu GH, Shen QY, et al. Dezocine prevents sufentanil-induced cough during general anesthesia induction: a randomised controlled trial [J]. Pharmacol Rep, 2015, 67(1): 52-55.
- [9] Hung KC. The possible mechanism of clonidine to suppress fentanyl-induced coughing [J]. Acta Anaesthesiol Scand, 2009, 53(9): 1227-1228.
- [10] 毕永红, 李冬梅, 张瑞芹. 右美托咪啶滴鼻对舒芬太尼引起咳嗽反射的影响[J]. 临床麻醉学杂志, 2012, 28(12): 1170-1171.
- [11] 黄桂华, 谭正泉, 马世颖. 舒芬太尼不同给药方式全麻诱导对患者呛咳的影响[J]. 重庆医学, 2013, 42(31): 3822-3823.
- [12] An LJ, Gui B, Su Z, et al. Magnesium sulfate inhibits sufentanil-induced cough during anesthetic induction [J]. Int J Clin Exp Med, 2015, 8(8): 13864-13868.
- [13] 王秀莹, 张成明, 孙万里, 等. 静注氯胺酮预防舒芬太尼诱导所致咳嗽反应效果观察[J]. 山东医药, 2009, 49(39): 102.

(收稿日期: 2015-12-23)